Phase I clinical study of humanized BCMA-single-domain antibodies targeting CAR-T in patients with relapsed or refractory multiple myeloma

Article Figures & Data

Table 1

Grade ≥3 treatment-emergent adverse events during the study

Grade ≥3 adverse events	2.5 × 10⁶ CAR-BCMA/kg (n = 3)	5.0 × 10⁶ CAR-BCMA/kg (n = 11)	7.5 × 10⁶ CAR-BCMA/kg (n = 1)	Total (n = 15)
Hematologic toxicities, n (%)
Neutropenia	3 (100.0)	10 (90.9)	1	14 (93.3)
Leukopenia	3 (100.0)	8 (72.7)	1	12 (80.0)
Lymphopenia	2 (66.7)	8 (72.7)	1	11 (73.3)
Anemia	2 (66.7)	6 (54.5)	1	9 (60.0)
Thrombocytopenia	0	3 (27.3)	1	4 (26.7)
Myelosuppression	0	1 (9.1)	0	1 (6.7)
Infectious disease, n (%)
Infection	0	2 (18.2)	1	3 (20)
Upper respiratory infection	0	1 (9.1)	0	1 (6.7)
Escherichia sepsis	0	1 (9.1)	0	1 (6.7)
Infectious enterocolitis	0	1 (9.1)	0	1 (6.7)
Pneumonia	0	1 (9.1)	0	1 (6.7)
Metabolic and nutritional diseases, n (%)
Hypokalemia	0	2 (18.2)	0	2 (13.3)
Kidney and urological diseases, n (%)
Renal calculus	0	1 (9.1)	0	1 (6.7)
Others, n (%)
Hypofibrinogenemia	0	1 (9.1)	0	1 (6.7)
Ferritin increased	1 (33.3)	1 (9.1)	0	2 (13.3)
Interleukin increased	0	1 (9.1)	0	1 (6.7)